European Union directive 2014/85/EU on driver licensing in obstructive sleep apnoea: early experiences with its application in the UK

Dipansu Ghosh; Thomas W. Mackay; Renata L. Riha

doi:10.1183/20734735.008016

Tables

Supplementary Materials

Table 1

Excessive sleepiness, including obstructive sleep apnoea syndrome

	Group 1: car and motorcycle	Group 2: bus and lorry
Excessive sleepiness including due to mild obstructive sleep apnoea syndrome AHI <15 (mild) on the or equivalent sleep study measure	Must not drive but may not need to notify the DVLA Driving may resume only after satisfactory symptom control	Must not drive and must notify the DVLA Driving may be licensed again once control of symptoms is satisfactory The DVLA will require a specialist's confirmation of ongoing adherence to treatment Licensing is subject to review, usually annually
Obstructive sleep apnoea syndrome, moderate and severe apnoeas with sleepiness AHI 15-29 (moderate) or ≥30 (severe) or equivalent sleep study measure	Must not drive and must notify the DVLA This requirement also applies for a suspected diagnosis yet to be confirmed Subsequent licensing will require control of condition sleepiness improved treatment adherence The DVLA will need medical confirmation of the above, and the driver must confirm review to be undertaken every annually at the minimum	Must not drive and must notify the DVLA This requirement also applies for a suspected diagnosis yet to be confirmed Subsequent licensing will require control of condition sleepiness improved treatment adherence The DVLA will need medical confirmation of the above, and the driver must confirm review to be undertaken every 3 years at the minimum
Obstructive sleep apnoea, moderate and severe apnoeas without sleepiness AHI 15-29 (moderate) or ≥30 (severe) or equivalent sleep study measure	Must not drive but need not notify the DVLA Driving may resume once associated symptoms such as poor concentration have been brought under control	Must not drive but need not notify the DVLA Driving may resume once associated symptoms such as poor concentration have been brought under control